Objective: Mutations in ion channels genes are potential cause of cardiomyopathy. The SCN5A gene (sodium channel, voltage gated, type V alpha subunit gene; 3p21) belongs to the family of cardiac sodium channel genes. Mutations in SCN5A gene lead to decreased Na+ current and ion unbalance. The SCN5A gene mutations are found in approximately 2% of patients with dilated cardiomyopathy (DCM), and they may be potential phenotype modifiers in hypertrophic cardiomyopathy (HCM). The role of SCN5A gene mutations in cardiomyopathy is not fully elucidated.
Methods: Three selected exons (12, 20, and 21) of the SCN5A gene in the cohort of 58 East Slovak patients with dilated and HCM were analyzed by the Sanger sequencing method in order to detect etiopathogenic mutations associated with dilated and HCM.
Results: The mutation screening of three selected exons of SCN5A gene in the cohort of 27 DCM, 12 HCM patients, and 16 controls identified 10 missense genetic variants. Three of them (T1247I, A1260D, and G1262S), all in exon 21 of the SCN5A gene, were potentially damaging and disease-causing variants.
Conclusion: Data from this study demonstrate that SCN5A gene variants have important role in the etiopathogenesis of dilated and HCM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816823 | PMC |
| http://dx.doi.org/10.1002/jcla.22037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High Glucose Sensitizes Male and Female Rat Cardiomyocytes to Wnt/β-Catenin Signaling.
Biomolecules
December 2024
Cardiac Electrophysiology Laboratory, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.
Wnt/β-catenin signaling has been shown to regulate gene expressions in cardiomyocytes. However, it is not known if this effect is dependent on the sex of cells or the glucose level in the culture medium. In the present study, ventricular myocytes were prepared from male and female neonatal rats and maintained in either a glucose-rich (25 mM) medium or a low-glucose (3 mM), lipid-rich medium.
View Article and Find Full Text PDFA novel SCN3B in-frame codon deletion in a Brugada syndrome patient: Implications for disrupted Na1.5 function.
J Mol Cell Cardiol
January 2025
Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK. Electronic address:
Introduction: Brugada Syndrome (BrS) is an inherited arrhythmia syndrome characterised by ST-segment elevation in the right precordial ECG leads and is associated with an increased risk of sudden cardiac death. We identify and characterise a novel SCN3B variant encoding the regulatory β3-subunit of the cardiac voltage-gated sodium channel, Na1.5.
View Article and Find Full Text PDFThe impact of common and rare genetic variants on bradyarrhythmia development.
Nat Genet
January 2025
Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, MA, USA.
To broaden our understanding of bradyarrhythmias and conduction disease, we performed common variant genome-wide association analyses in up to 1.3 million individuals and rare variant burden testing in 460,000 individuals for sinus node dysfunction (SND), distal conduction disease (DCD) and pacemaker (PM) implantation. We identified 13, 31 and 21 common variant loci for SND, DCD and PM, respectively.
View Article and Find Full Text PDFWe present a case of HCN4 gene mutation presenting with atrial standstill and stroke in the young.
View Article and Find Full Text PDFThe sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner.
J Mol Cell Cardiol
December 2024
Department of Pharmacology, Alberta Diabetes Institute, Faculty of Medicine and Dentistry, University of Alberta, 7-55 Medical Sciences Building, Edmonton T6G 2H7, Alberta, Canada. Electronic address:
Article Synopsis
- Sodium/glucose cotransporter 2 inhibitors (SGLT2is), such as empagliflozin, show potential heart protection benefits in individuals with or without diabetes and can inhibit a key cardiac sodium current linked to congenital long QT syndrome type 3 (LQT3).
- Researchers used the whole-cell patch-clamp technique to study how empagliflozin affects late sodium current (late I) in various LQT3 mutations of the Nav1.5 channel.
- Empagliflozin specifically inhibited late I in certain mutations without altering channel kinetics, suggesting it could be an effective targeted treatment for patients with LQT3 mutations in the inactivation gate area.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!